Want to join the conversation?
$BSX's selling, general and administrative (SG&A) expenses for 1Q16 increased by 7% from last year and were 130 basis points lower as percentage of net sales. The decline in SG&A as percentage of sales was due to recent suspension of medical device tax, as well as targeted initiatives that have been focused on reducing SG&A.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.